Protara Therapeutics, Inc.
TARAHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. Valued at $232.8M, TARA is a micro-cap name in its sector. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Market Cap
$232.8M
Beta
1.49
P/E (TTM)
—
P/E (Fwd)
-2.33
EPS (TTM)
$-1.35
EPS (Fwd)
$-1.69
ROE
-45.8%
ROA
-28.8%
Cash
$142.5M
Total Debt
$2.7M
Free CF
-$40.5M
52W Change
26.0%
Annual Financials
Cash vs Debt
Where TARA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TARA finished 19.43% below its 150-day moving average ($4.89) and 23.50% below its 200-day moving average ($5.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TARA overbought or oversold?
At the September 3, 2026 close, TARA's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Protara Therapeutics, Inc. holds $142.5M in cash against $2.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$40.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -45.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Protara Therapeutics, Inc. and its sector.